

AMENDMENTS TO THE CLAIMS

A detailed listing of all claims that are, or were, in the present application, irrespective of whether the claim(s) remains under examination in the application are presented below. The claims are presented in ascending order and each includes one status identifier. Those claims not cancelled or withdrawn but amended by the current amendment utilize the following notations for amendment: 1. deleted matter is shown by strikethrough for six or more characters and double brackets for five or less characters; and 2. added matter is shown by underlining.

1. (Withdrawn, Currently Amended) A medical device, the device comprising a biocompatible, biodegradable filler material in Denovillier's space, wherein the device comprises at least a portion that has a shape that substantially conforms to Denovillier's space wherein the device is biodegradable in the patient to remove the device.

2. (Withdrawn) The medical device of claim 2 wherein the filler material comprises an extracellular matrix molecule.

3. (Withdrawn) The medical device of claim 2 wherein the extracellular matrix molecule is collagen.

4. (Withdrawn) The medical device of claim 2 wherein the filler material consists essentially of collagen.

5. (Withdrawn) The medical device of claim 1 wherein the filler material comprises at least one polysaccharide.
6. (Withdrawn) The medical device of claim 5 wherein the at least one polysaccharide is hyaluronic acid.
7. (Withdrawn) The medical device of claim 1 wherein the filler material is biodegradable in vivo in less than approximately 90 days.
8. (Withdrawn) The medical device of claim 1 further comprising a degradation inhibitor.
9. (Withdrawn) The medical device of claim 1 wherein the filler material is a member of the group consisting of alginate, gelatin, fibrin, fibrinogen, albumin, polylactide, polyglycolide, polycaprolactone, poly(alpha-hydroxy acid), polyethylene glycol, thixotropic polymers, thermoreversible polymers, and mixtures thereof.
10. (Withdrawn) The medical device of claim 1 further comprising a radio opaque marker.
- 11-12 (Cancelled)
13. (Withdrawn) The medical device of claim 1 further comprising an osmotic agent that causes water to become associated with the filler material by osmosis.

14. (Withdrawn) The medical device of claim 1 further comprising a buffering agent.
15. (Withdrawn) The medical device of claim 1 wherein the filler material comprises a synthetic polymer.
16. (Withdrawn) The medical device of claim 1 wherein the device has a volume in the range of 10 to 200 cubic centimeters.
17. (Currently Amended) A method of ~~administering~~ delivering a therapeutic dose of radiation to a patient comprising introducing a biocompatible, biodegradable filler device [[to]] between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, and ~~administering~~ treating the second tissue location with the therapeutic a dose of radiation ~~radioactivity to the second tissue location~~ so that the presence of the filler device causes the first tissue location to receive less of the dose of radioactivity compared to the amount of the dose of radioactivity the first tissue location would receive in the absence of the filler device, wherein the filler device is removed by biodegradation of the filler device in the patient.
18. (Original) The method of claim 17 wherein the first tissue location is associated with the rectum and the second tissue location is associated with the prostate gland.
19. (Original) The method of claim 17 wherein the filler is introduced into Denovillier's space.

20. (Original) The method of claim 17 wherein the first tissue location is located on a tissue that is a member of the group consisting of an ovary, a nerve, a cartilage, a bone, and a brain.
21. (Original) The method of claim 17 wherein the filler comprises a member of the group consisting of alginate, gelatin, fibrin, fibrinogen, albumin, polylactide, polyglycolide, polycaprolactone, poly(alpha-hydroxy acid), polyethylene glycol, thixotropic polymers, thermoreversible polymers, and mixtures thereof.
22. (Original) The method of claim 17 wherein the filler comprises at least one therapeutic agent.
23. (Original) The method of claim 22 wherein the at least one therapeutic agent is a member of the group consisting of an anti-inflammatory drug, an antibiotic, an antimycotics, a hemostat, a steroid, and an analgesic.
24. (Original) The method of claim 17 wherein the filler is biodegradable in vivo in less than approximately 90 days.
25. (Original) The method of claim 17 wherein the filler is an expandable device.
26. (Cancelled)

27. (Previously Presented) The method of claim 25 wherein the expandable device is a sponge.
28. (Cancelled)
29. (Previously Presented) The method of claim 17 wherein the biocompatible, biodegradable material comprises an extracellular matrix molecule.
30. (Previously Presented) The method of claim 17 wherein the biocompatible, biodegradable material consists essentially of collagen.
31. (Previously Presented) The method of claim 17 wherein the filler comprises at least one polysaccharide.
32. (Original) The method of claim 31 wherein the at least one polysaccharide is hyaluronic acid.
33. (Previously Presented) The method of claim 28 wherein the filler further comprises a member of the group consisting of a degradation inhibitor, a radio opaque marker, and an osmotic agent that causes water to become associated with the filler material by osmosis.
34. (Previously Presented) The method of claim 28 wherein the filler further comprises a buffering agent.

35. (Original) The method of claim 17 wherein the filler comprises a member of the group consisting of a degradation inhibitor, a radio opaque marker, and an osmotic agent that causes water to become associated with the filler material by osmosis.

36. (Original) The method of claim 17 wherein the filler comprises a buffering agent.

37. (Original) The method of claim 17 wherein the filler material comprises a synthetic polymer.

38. (Original) The method of claim 17 wherein the filler occupies a volume in the range of about 10 to about 200 cubic centimeters in a patient.

39. (Withdrawn, Currently Amended) A kit, the kit comprising a biodegradable filler device for effectively delivering a therapeutic dose of radiation to a target tissue and instructions for placing the filler device between a first tissue location and the target tissue ~~a second tissue~~ location to increase a distance between the first tissue location and the target ~~second~~ tissue location in combination with a therapeutic dose of radiation so that the increased distance would change an amount of radiation received by ~~at least the first tissue location or the second tissue~~ location when ~~at least the first tissue location or the target~~ target ~~second~~ tissue location receives [[a]] the therapeutic dose of radiation, wherein the device is biodegradable to remove the device from the patient.

40. (Withdrawn, Currently Amended) The kit of claim 39 wherein the instructions provide for introducing the filler into Denovillier's space with the target tissue being a prostate gland and the first tissue being a rectum.
41. (Withdrawn, Currently Amended) The kit of claim 39 wherein the filler device is an expandable device.
42. (Cancelled)
43. (Withdrawn, Currently Amended) The kit of claim 39 wherein the instructions describe [[a]] the first tissue location located on a tissue that is a member of the group consisting of an ovary, a nerve, a cartilage, a bone, and a brain.
44. (Withdrawn, Currently Amended) The kit of claim 39 wherein the instructions describe the first tissue location [[as]] being ~~associated with~~ the rectum and the target ~~second~~ tissue location [[is]] being ~~associated with~~ the prostate gland.
45. (Withdrawn) The kit of claim 39 wherein the filler comprises a member of the group consisting of alginate, gelatin, fibrin, fibrinogen, albumin, polylactide, polyglycolide, polycaprolactone, poly(alpha-hydroxy acid), polyethylene glycol, thixotropic polymers, thermoreversible polymers, and mixtures thereof.

46. (Withdrawn) The kit of claim 39 wherein the filler comprises at least one therapeutic agent.
47. (Withdrawn) The kit of claim 46 wherein the at least one therapeutic agent is a member of the group consisting of an anti-inflammatory drug, an antibiotic, an antimycotics, a hemostat, a steroid, and an analgesic.
48. (Withdrawn) The kit of claim 39 wherein the filler is biodegradable in vivo in less than approximately 90 days.
49. (Withdrawn) The kit of claim 39 wherein the filler comprises a biocompatible, biodegradable material.
50. (Withdrawn) The kit of claim 39 wherein the biocompatible, biodegradable material comprises an extracellular matrix molecule.
51. (Withdrawn) The kit of claim 39 wherein the biocompatible, biodegradable material consists essentially of collagen, hyaluronic acid, or a mixture of thereof.
52. (Withdrawn) The kit of claim 39 wherein the filler comprises at least one polysaccharide.

53. (Withdrawn) The kit of claim 39 wherein the at least one polysaccharide is hyaluronic acid.
54. (Withdrawn) The kit of claim 39 wherein the filler further comprises a member of the group consisting of a degradation inhibitor, a radio opaque marker, and an osmotic agent that causes water to become associated with the filler material by osmosis.
55. (Withdrawn) The method of claim 39 wherein the filler further comprises a buffering agent.
56. (Withdrawn, Currently Amended) The kit of claim 39 further comprising a delivery device for delivering the filler.
57. (Withdrawn, Currently Amended) The kit of claim [[39]] 56 wherein the device for delivering the filler comprises a syringe.
58. (Cancelled)
59. (Withdrawn) The kit of claim 39 wherein the filler comprises a synthetic polymer.
60. (Withdrawn) The kit of claim 39 wherein the filler has a volume in the range of 10 to 200 cubic centimeters after being introduced into a patient.

61. (Withdrawn) The kit of claim 39 wherein the filler has a volume in the range of 5 to 400 cubic centimeters after being introduced into a patient.
62. (Previously Presented) The method of claim 17 wherein the filler remains in the patient for more than approximately four weeks.

Please add the following new claims:

63. (New) The method of claim 17 wherein the presence of the filler causes the first tissue location to receive less than about 50% of the dose of radioactivity compared to the amount of the dose of radioactivity the first tissue location would receive in the absence of the filler.
64. (New) The method of claim 17 wherein the dose of therapeutic radiation is at least 70 Gy.